nimodipine , a dihydropyridine calcium channel blocker , was evaluated in vitro for its ability to inhibit platelet aggregation induced by b16 amelanotic melanoma ( b16a ) and walker 256 carcinosarcoma ( w256 ) cells , and for its ability to inhibit platelet-enhanced b16a and w256 adhesion to rat microvascular endothelial cells .
C0007140
carcinosarcoma
C0007634
cells